---
schema_version: "secwatch.filing_event.v1"
accession: "0001628908-26-000084"
form_type: "8-K"
ticker: "EVH"
cik: "0001628908"
company_name: "Evolent Health, Inc."
filed_at: "2026-08-06T11:03:53+00:00"
generated_at: "2026-08-06T11:06:24.803629+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolent Q2 revenue $652.5M (+47% YoY); net loss narrows; new oncology partnership to add $300M annual revenue

## Summary
- Revenue $652.5M vs $444.3M YoY; net loss attributable to common $28.4M vs $51.1M.
- Adjusted EBITDA $28.1M (4.3% margin) vs $37.5M (8.5% margin) YoY; Medical Expense Ratio 95.3% vs 80.0%.
- Guides 2027 revenue growth >25% vs 2026; midpoint of 2027 Adjusted EBITDA at or above $150M.
- New Oncology Performance Suite partnership covering ~1.5M lives, expected launch Dec 2026, ~$300M annualized revenue.
- Existing STSS client expands; annualized revenue <$5M; company evaluating debt reduction initiatives.

## SEC filing metadata
- accession: 0001628908-26-000084
- form_type: 8-K
- ticker: EVH
- cik: 0001628908
- company_name: Evolent Health, Inc.
- filed_at: 2026-08-06T11:03:53+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628908/000162890826000084/0001628908-26-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628908/000162890826000084/evh-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628908-26-000084
- JSON: https://secwatch.observer/filing/0001628908-26-000084.json
- Plain text: https://secwatch.observer/filing/0001628908-26-000084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.